- Home
- LSF vs VRCA Comparison
LSF vs VRCA Comparison
Compare LSF & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | VRCA |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 32.7M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LSF | VRCA |
|---|---|---|
| Price | $2.20 | $8.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 118.3K | ★ 387.1K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | $30,829,000.00 |
| Revenue This Year | $18.05 | $373.65 |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 17.73 | ★ 234.73 |
| 52 Week Low | $2.15 | $3.28 |
| 52 Week High | $8.99 | $10.50 |
Technical Indicators
Market Signals| Indicator | LSF | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 26.51 | 66.24 |
| Support Level | $2.18 | $6.26 |
| Resistance Level | $2.78 | $9.78 |
| Average True Range (ATR) | 0.18 | 1.16 |
| MACD | 0.05 | 0.30 |
| Stochastic Oscillator | 9.86 | 74.02 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.